Acrivon Therapeutics (ACRV) Treasury Shares (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Treasury Shares of $147539.0 for Q1 2026, down 81.24% year-over-year from $786501.0 in Q1 2025, and down 33.62% quarter-over-quarter from $222252.0 in Q4 2025.
Acrivon Therapeutics (ACRV) Treasury Shares (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Treasury Shares for 6 consecutive years, with $147539.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Treasury Shares fell 81.24% year-over-year to $147539.0; the TTM figure through Mar 2026 stood at $147539.0 (down 81.24% YoY), while the FY2025 annual figure was $222252.0, down 77.22% from the prior year.
- Treasury Shares retreated to $147539.0 in Q1 2026 per ACRV's latest filing, from $222252.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $27.5 million in Q1 2022 and bottomed at $147539.0 in Q1 2026.
- Historically, Treasury Shares has averaged $5.8 million across 5 years, with a median of $1.6 million in 2024.
- On a YoY basis, Treasury Shares climbed as much as 177.36% in 2022 and fell as far as 93.49% in 2022.
- Acrivon Therapeutics' Treasury Shares stood at $1.8 million in 2022, then slipped by 1.52% to $1.8 million in 2023, then slumped by 44.57% to $975550.0 in 2024, then plunged by 77.22% to $222252.0 in 2025, then plunged by 33.62% to $147539.0 in 2026.
- Business Quant data shows ACRV's Treasury Shares at $147539.0 in Q1 2026, $222252.0 in Q4 2025, and $406972.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.02 Mn |
| Jun 30, 2026 | 1.02 Mn |
| Mar 31, 2026 | 147,539.00 |
| Mar 31, 2026 | 147,539.00 |
| Dec 31, 2025 | 222,252.00 |
| Dec 31, 2025 | 222,252.00 |
| Sep 30, 2025 | 406,972.00 |
| Sep 30, 2025 | 406,972.00 |
| Jun 30, 2025 | 595,355.00 |
| Jun 30, 2025 | 595,355.00 |
| Mar 31, 2025 | 786,501.00 |
| Mar 31, 2025 | 786,501.00 |
| Dec 31, 2024 | 975,550.00 |
| Dec 31, 2024 | 975,550.00 |
| Sep 30, 2024 | 1.16 Mn |
| Sep 30, 2024 | 1.16 Mn |
| Jun 30, 2024 | 1.47 Mn |
| Jun 30, 2024 | 1.47 Mn |
| Mar 31, 2024 | 1.62 Mn |
| Mar 31, 2024 | 1.62 Mn |